NO312414B1 - 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende demog deres anvendelse - Google Patents

4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende demog deres anvendelse Download PDF

Info

Publication number: NO312414B1
Authority: NO; Norway
Prior art keywords: formula; alkyl; compound; fluorine; stands
Prior art date: 1996-06-24

Application number

NO19972943A

Other languages

English (en)

Norwegian (no)

Other versions

NO972943D0 (no

NO972943L (no

Inventor

Hans Georg Boeger

Axel Hoffmann

Gerhard Jaehne

Norbert Krass

Hans-Ludwig Schaefer

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-24

Filing date

1997-06-23

Publication date

2002-05-06

1997-06-23 Application filed by Hoechst Ag filed Critical Hoechst Ag

1997-06-23 Publication of NO972943D0 publication Critical patent/NO972943D0/no

1997-12-29 Publication of NO972943L publication Critical patent/NO972943L/no

2002-05-06 Publication of NO312414B1 publication Critical patent/NO312414B1/no

Links

238000000034 method Methods 0.000 title claims description 19
238000002360 preparation method Methods 0.000 title claims description 11
239000003814 drug Substances 0.000 title claims description 9
230000008569 process Effects 0.000 title claims description 5
SHGZREYDEWHPDB-UHFFFAOYSA-N 4-amino-2-(carbamoylamino)pyrimidine-5-carboxamide Chemical class NC(=O)NC1=NC=C(C(N)=O)C(N)=N1 SHGZREYDEWHPDB-UHFFFAOYSA-N 0.000 title claims description 4
229940079593 drug Drugs 0.000 title description 4
150000003839 salts Chemical class 0.000 claims abstract description 20
229910052731 fluorine Inorganic materials 0.000 claims abstract description 19
125000000217 alkyl group Chemical group 0.000 claims abstract description 10
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
229910052794 bromium Inorganic materials 0.000 claims abstract description 7
229910052801 chlorine Inorganic materials 0.000 claims abstract description 5
150000001875 compounds Chemical class 0.000 claims description 60
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 18
239000011737 fluorine Substances 0.000 claims description 18
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 9
239000001257 hydrogen Substances 0.000 claims description 8
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
239000000460 chlorine Substances 0.000 claims description 4
150000002431 hydrogen Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
208000017170 Lipid metabolism disease Diseases 0.000 claims description 3
229940126601 medicinal product Drugs 0.000 claims description 3
208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 5
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000004414 alkyl thio group Chemical group 0.000 abstract 2
NKTWBSSRNCDNCD-UHFFFAOYSA-N 4-amino-2-(2-oxoimidazolidin-1-yl)pyrimidine-5-carboxamide Chemical class N1=C(N)C(C(=O)N)=CN=C1N1C(=O)NCC1 NKTWBSSRNCDNCD-UHFFFAOYSA-N 0.000 abstract 1
125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
238000005160 1H NMR spectroscopy Methods 0.000 description 17
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 17
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
239000013543 active substance Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
108020004999 messenger RNA Proteins 0.000 description 10
239000000126 substance Substances 0.000 description 10
238000005481 NMR spectroscopy Methods 0.000 description 8
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 8
102000000853 LDL receptors Human genes 0.000 description 7
108010001831 LDL receptors Proteins 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000015556 catabolic process Effects 0.000 description 5
238000006731 degradation reaction Methods 0.000 description 5
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000011097 chromatography purification Methods 0.000 description 3
230000000055 hyoplipidemic effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
238000002156 mixing Methods 0.000 description 3
238000010992 reflux Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
230000000638 stimulation Effects 0.000 description 3
IXPCHRDFJPINFB-UHFFFAOYSA-N 4,4-dimethyl-2-oxoimidazolidine-1-carboximidamide Chemical compound CC1(C)CN(C(N)=N)C(=O)N1 IXPCHRDFJPINFB-UHFFFAOYSA-N 0.000 description 2
QNHJNFAMXXEFIU-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylic acid Chemical compound O=C1NC(C)(C)CN1C1=NC=C(C(O)=O)C(N)=N1 QNHJNFAMXXEFIU-UHFFFAOYSA-N 0.000 description 2
CANCNNXFBGDUHY-UHFFFAOYSA-N 4-amino-2-(carbamoylamino)pyrimidine-5-carboxylic acid Chemical compound NC(=O)NC1=NC=C(C(O)=O)C(N)=N1 CANCNNXFBGDUHY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
229940126062 Compound A Drugs 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
230000001028 anti-proliverative effect Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000008033 biological extinction Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 2
230000001472 cytotoxic effect Effects 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
ZFCHNZDUMIOWFV-UHFFFAOYSA-N pyrimidine-2-carboxylic acid Chemical compound OC(=O)C1=NC=CC=N1 ZFCHNZDUMIOWFV-UHFFFAOYSA-N 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000007921 spray Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
238000005406 washing Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
MWDNZMWVENFVHT-UHFFFAOYSA-L (2-decoxy-2-oxoethyl)-[2-[2-[(2-decoxy-2-oxoethyl)-dimethylazaniumyl]ethylsulfanyl]ethyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCOC(=O)C[N+](C)(C)CCSCC[N+](C)(C)CC(=O)OCCCCCCCCCC MWDNZMWVENFVHT-UHFFFAOYSA-L 0.000 description 1
125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
ANKGBUOHLNUQQF-UHFFFAOYSA-N 2-cyano-3-ethoxy-n-[3-(trifluoromethoxy)phenyl]prop-2-enamide Chemical compound CCOC=C(C#N)C(=O)NC1=CC=CC(OC(F)(F)F)=C1 ANKGBUOHLNUQQF-UHFFFAOYSA-N 0.000 description 1
SADHVOSOZBAAGL-UHFFFAOYSA-N 3-(trifluoromethoxy)aniline Chemical compound NC1=CC=CC(OC(F)(F)F)=C1 SADHVOSOZBAAGL-UHFFFAOYSA-N 0.000 description 1
MVJUWYYHFCSTBT-UHFFFAOYSA-N 4,4-dimethyl-2-oxoimidazolidine-1-carboximidamide;hydrobromide Chemical compound Br.CC1(C)CN(C(N)=N)C(=O)N1 MVJUWYYHFCSTBT-UHFFFAOYSA-N 0.000 description 1
NPFJOSKCSJJZPP-UHFFFAOYSA-N 4-amino-2-(2-oxoimidazolidin-1-yl)pyrimidine-5-carboxylic acid Chemical class C1=C(C(O)=O)C(N)=NC(N2C(NCC2)=O)=N1 NPFJOSKCSJJZPP-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
206010006417 Bronchial carcinoma Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
HXSYAJRDYBKIQG-UHFFFAOYSA-N O=C1NC(C)(C)CN1C1(C(=O)NC=2C(=CC=C(OC(F)(F)F)C=2)F)N=C(N)C=CN1 Chemical compound O=C1NC(C)(C)CN1C1(C(=O)NC=2C(=CC=C(OC(F)(F)F)C=2)F)N=C(N)C=CN1 HXSYAJRDYBKIQG-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010038389 Renal cancer Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
150000003931 anilides Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
239000000872 buffer Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
239000013078 crystal Substances 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000010586 diagram Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
VMEUCSINSIZDPO-UHFFFAOYSA-N n-methyl-2-(trifluoromethoxy)aniline Chemical compound CNC1=CC=CC=C1OC(F)(F)F VMEUCSINSIZDPO-UHFFFAOYSA-N 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
238000007363 ring formation reaction Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000035939 shock Effects 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
150000003511 tertiary amides Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
238000009736 wetting Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO19972943A 1996-06-24 1997-06-23 4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende demog deres anvendelse NO312414B1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19625089A DE19625089A1 (de)	1996-06-24	1996-06-24	4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

Publications (3)

Publication Number	Publication Date
NO972943D0 NO972943D0 (no)	1997-06-23
NO972943L NO972943L (no)	1997-12-29
NO312414B1 true NO312414B1 (no)	2002-05-06

Family

ID=7797762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19972943A NO312414B1 (no)	1996-06-24	1997-06-23	4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdende demog deres anvendelse

Country Status (11)

Country	Link
US (1)	US5939424A (2)
EP (1)	EP0816358B1 (2)
JP (1)	JP4101906B2 (2)
AT (1)	ATE281452T1 (2)
CA (1)	CA2208630C (2)
DE (2)	DE19625089A1 (2)
DK (1)	DK0816358T3 (2)
ES (1)	ES2230575T3 (2)
MX (1)	MX9704704A (2)
NO (1)	NO312414B1 (2)
PT (1)	PT816358E (2)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19625088A1 (de) *	1996-06-24	1998-01-02	Hoechst Ag	4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US6887712B1 (en) *	1998-11-09	2005-05-03	Atherogenics, Inc.	Methods and compositions to lower plasma cholesterol levels
ATE314362T1 (de) *	1999-10-12	2006-01-15	Takeda Pharmaceutical	Pyrimidin-5-carboximidverbindungen, verfahren zur herstellung derselben und deren verwendung
US7176310B1 (en)	2002-04-09	2007-02-13	Ucb Sa	Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents
JP2007518816A (ja) *	2004-01-23	2007-07-12	アムジエン・インコーポレーテツド	バニロイド受容体リガンド及び炎症性及び神経因性疼痛の治療におけるこれらの使用
JP2011057661A (ja) *	2009-08-14	2011-03-24	Bayer Cropscience Ag	殺虫性カルボキサミド類

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2853220A1 (de) *	1978-12-09	1980-07-03	Hoechst Ag	Neue amino-pyrimidin-carbanilide, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
DE3522940A1 (de) *	1985-06-27	1987-01-08	Hoechst Ag	4-amino-2-(imidazolidin-2-on-1-yl)-pyrimidin-5-carbonsaeure-(n-(3-trifluormethyl-phenyl)-amide) zur antithrombotischen prophylaxe und behandlung sowie ihre verwendung zur herstellung von antithrombotisch wirksamen arzneimitteln
EP0577877B1 (en) *	1991-09-04	1995-10-18	Sumitomo Electric Industries, Ltd.	Adjusting shim
ES2098570T3 (es) *	1992-02-22	1997-05-01	Hoechst Ag	Amidas de un acido 4-amino-2-ureido-pirimidina-5-carboxilico, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
ATE158581T1 (de) *	1992-02-22	1997-10-15	Hoechst Ag	Lösliche salze von 4-amino-2-(4,4-dimethyl- imidazolidin-2-on-1-yl)-pyrimidin-5 -carbonsäure- n-methyl-n-(3-trifluormethyl-phenyl)- amid, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel und ausgangsprodukte
DE19625088A1 (de) *	1996-06-24	1998-01-02	Hoechst Ag	4-Amino-2-ureido-pyrimidin-5-carbonsäureamide, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung

1996
- 1996-06-24 DE DE19625089A patent/DE19625089A1/de not_active Withdrawn
1997
- 1997-06-04 US US08/868,991 patent/US5939424A/en not_active Expired - Lifetime
- 1997-06-12 DE DE59712053T patent/DE59712053D1/de not_active Expired - Lifetime
- 1997-06-12 DK DK97109547T patent/DK0816358T3/da active
- 1997-06-12 PT PT97109547T patent/PT816358E/pt unknown
- 1997-06-12 AT AT97109547T patent/ATE281452T1/de active
- 1997-06-12 EP EP97109547A patent/EP0816358B1/de not_active Expired - Lifetime
- 1997-06-12 ES ES97109547T patent/ES2230575T3/es not_active Expired - Lifetime
- 1997-06-23 MX MX9704704A patent/MX9704704A/es active IP Right Grant
- 1997-06-23 CA CA002208630A patent/CA2208630C/en not_active Expired - Fee Related
- 1997-06-23 JP JP16581597A patent/JP4101906B2/ja not_active Expired - Fee Related
- 1997-06-23 NO NO19972943A patent/NO312414B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO972943D0 (no)	1997-06-23
DE19625089A1 (de)	1998-01-02
CA2208630C (en)	2006-07-11
JP4101906B2 (ja)	2008-06-18
DK0816358T3 (da)	2005-03-07
CA2208630A1 (en)	1997-12-24
NO972943L (no)	1997-12-29
US5939424A (en)	1999-08-17
EP0816358B1 (de)	2004-11-03
JPH1072463A (ja)	1998-03-17
DE59712053D1 (de)	2004-12-09
ES2230575T3 (es)	2005-05-01
MX9704704A (es)	1997-12-31
PT816358E (pt)	2005-01-31
EP0816358A1 (de)	1998-01-07
ATE281452T1 (de)	2004-11-15

Legal Events

Date	Code	Title	Description
2015-01-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
RU2522578C2 (ru)	2014-07-20	Производные фенилпиримидона, фармацевтические композиции, способы их получения и применения
AU2012296662A1 (en)	2014-03-27	Lysophosphatidic acid receptor antagonists
NO180678B (no)	1997-02-17	N-substituerte heterocykliske forbindelser og farmasöytisk preparat
US4431663A (en)	1984-02-14	Treatment of psychosis with meta-sulfonamido-benzamide derivatives
AU715493B2 (en)	2000-02-03	Selective beta 3 adrenergic agonists
DK157862B (da)	1990-02-26	Analogifremgangsmaade til fremstilling af imidazolylphenylamidiner eller farmaceutisk acceptable syreadditionssalte deraf
CN1208409A (zh)	1999-02-17	新颖苄酰基胍衍生物,其制法及其在药物组合物制备中的用途
JP4717210B2 (ja)	2011-07-06	男性の勃起機能障害の処置のための５−ヘテロシクリルピラゾロ［４，３−ｄ］ピリミジン−７−オン
AU658266B2 (en)	1995-04-06	4-amino-2-ureidopyrimidine-5-carboxamides, a process for the preparation thereof, pharmaceuticals containing these compounds, and the use thereof
CN1204315A (zh)	1999-01-06	新颖的苯基脒衍生物,其制法及其作为医药组合物的用途
DK163581B (da)	1992-03-16	Kondenserede pyrazol-3-oxo-propannitrilderivater og fremgangsmaade til fremstilling deraf samt farmaceutiske praeparater indeholdende forbindelserne
JP4101906B2 (ja)	2008-06-18	４−アミノ−２−ウレイドピリミジン−５−カルボキサミド、それらの製法、これらの化合物を含有する医薬およびそれらの使用
US20040142850A1 (en)	2004-07-22	Benzimidazolidinone derivatives
US6232337B1 (en)	2001-05-15	Selective β3 adrenergic agonists
US3984563A (en)	1976-10-05	Antiinflammatory 2-imino-indolines and their pharmaceutical compositions
AU669463B2 (en)	1996-06-06	Soluble salts of 4-amino-2-(4,4-dimethylimidazolidin-2-on-1- yl)pyrimidine-5-carboxylic acid N-methyl-N-(3- trifluoromethylphenyl)amide, a process for the preparation thereof, the use thereof as pharmaceuticals and starting materials
SK61597A3 (en)	1997-11-05	6-methoxy-1h-benzotriazole-5-carboxamide derivatives, process for producing the same, and medicinal composition containing the same
NO312133B1 (no)	2002-03-25	4-amino-2-ureido-pyrimidin-5-karboksylsyreamider, fremgangsmåter for deres fremstilling, legemidler inneholdendedisse forbindelsene og deres anvendelse
NO162857B (no)	1989-11-20	Analogifremgangsmaate for fremstilling av terapeutisk aktive amidin-derivater av 2-substituert 4-fenylimidazol.
JP3529112B2 (ja)	2004-05-24	２−［２−（置換アミノ）ベンジルチオ］−５，６，７，８−テトラヒドロピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
JPH02178275A (ja)	1990-07-11	置換された３‐アミノシドノンイミン、その製造方法及びその使用方法
JPH05262718A (ja)	1993-10-12	５−置換アミノ−２−フェノキシスルホンアニリド化合物